肿瘤免疫治疗是通过激活或增强人体免疫系统来治疗肿瘤的方法，现已成为手术和放化疗之外的肿瘤生物治疗中重要的发展领域。细胞因子白介素7（IL-7）因其促进T淋巴细胞存活和增殖的作用成为肿瘤免疫治疗的研究热点。本课题组发现IL-7与凋亡受体CD95能够协同作用促进肿瘤患者外周血单个核细胞（PBMC）的存活和增殖，并且在体外细胞杀伤实验中具有更强的抗肿瘤活性，但其在裸鼠体内实验中杀伤肿瘤的功能以及其分子机制还有待进一步研究。本课题拟在前期发现的基础上进一步明确IL-7与CD95协同作用的PBMC的细胞亚群和表型变化，在裸鼠模型中进一步验证IL-7与CD95协同作用的PBMC的肿瘤杀伤活性，进而探究二者协同作用的PBMC活性增强的具体信号通路。本研究旨在为肿瘤免疫治疗提供更有效的细胞激活方法并探明其抗肿瘤活性增强的具体分子机制，为肿瘤免疫治疗提供更多的靶点。

Cancer immunotherapy is the treatment of cancer by activating or reinforcing the immune system. It has become an interest of research in the field of cancer biological therapy. Interleukin 7 (IL-7) is a potential therapeutic choice in cancer immunotherapy for its funtion as a survival and proliferation cytokine. We have found IL-7 and apoptosis receptor CD95 could synergistically promote survival and proliferation of PBMCs from post-operation post-chemotherapy cancer patients. Furthermore, these PBMCs possess cytotoxicity towards cancer cells in vitro. However, their in vivo anti-tumor function in nude mice and molecular mechanism warrant investigation. Our project aims to clarify the change of T cell subsets and phenotypes of PBMCs after IL-7/CD95 co-stimulation and to confirm their anti-tumor cytotoxicity in nude mice model. Furthermore, we are to disclose the signaling pathway of IL-7/CD95 reinforced anti-tumor response. Our research will provide a more effective method for lymphocytes stimulation and to investigate the specific mechanism of their increased anti-tumor response, thus provide more potential targets for cancer immunotherapy.